AEGiS-PRn: Antiviral Drug Discovery & Development Conference to Feature Big Pharma Advances in Respiratory/Influenza, HIV, & HBV/HCV in March, in Princeton, NJ

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Antiviral Drug Discovery & Development Conference to Feature Big Pharma Advances in Respiratory/Influenza, HIV, & HBV/HCV in March, in Princeton, NJ

PRNewswire - December 20, 1999

PRINCETON, N.J., Dec. 20 /PRNewswire/ -- A major new, international conference presenting the newest advances by the pharmaceutical industry in developing novel drugs to fight viral diseases, including respiratory/influenza, HIV, and hepatitis B & C, will take place on March 15-16, 2000 at the Hyatt Regency Hotel in Princeton, NJ, announces Strategic Research Institute.

The conference will feature new flu compounds targeting neuraminidase inhibitors to be presented by Roche (Tamiflu), Glaxo Wellcome (Relenza), and RW Johnson PRI (RWJ-270201); Agouron's protease inhibitor for rhinovirus infection, and clinical summary of ViroPharma's Pleconaril, a novel therapy for picornaviral disease, will also be featured.

In HIV, the conferences focuses on Trimeris' fusion inhibitor, T-20 and Merck's Integrase inhibitor; also featured will be new work on reverse transcriptase inhibitors (BioChem Pharma and DuPont), plus contribution from Glaxo Wellcome on resistance testing as a guide to antiretroviral discovery and development in light of the recent FDA Advisory Committee meeting.

The HBV/HCV section will feature discussion of Schering Plough's Ribavirin, Roche's Pegainterferon alfa-2a and contributions from Eli Lilly and Glaxo Wellcome; Emory University and Novirio Pharmaceuticals will present new data on nucleoside analogs and L-nucleosides, both having shown potent activity against hepatitis B.

To request the agenda and/or register, please contact Camille Coward of Strategic Research at ccoward@srinstitute.com (include company/university and mailing address) or by phone at 212-967-0095, ext 255; for information on sponsorship & exhibition contact Mark Alexay at 212-967-0095, x251 or malexay@hotmail.com .

SOURCE Strategic Research Institute L.P.

CONTACT: Camille Coward, 212-967-0095 ext. 255, or ccoward@srinstitute.com, or Mark Alexay, Sponsorship and Exhibition, 212-967-0095, ext. 251, or malexay@hotmail.com, both of the Strategic Research Institute L.P./

Web Site: http://www.srinstitute.com/
991220
PR991219

Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .